Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:HIKAL

HIKAL LIMITED

Healthcare › Pharmaceuticals & Biotechnology
₹202.25
at close · 28 Oct 2026
▼ 0.53 (-0.26%)
ThemesBiotechnology· growingBatteries & Energy Storage· mention

Latest filings

Next results: Tue, 3 Nov · Financial Results
  1. Hikal schedules Q2 and H1 FY27 earnings conference call · Board & Shareholder Meetings
  2. Board to approve Hikal's September 2026 quarterly results · Results
  3. Newspaper notice on special window to dematerialise old physical shares · Compliance
All filings ↓
Ask Nexa about HIKAL LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹1,735 Cr over the trailing twelve months.

Market Cap
₹2,498 Cr
P / E (TTM)
—
EV / EBITDA
18.7×
Div Yield
0.49%
Growth
-0.1%▼
Revenue 5y CAGR
PAT — · EBITDA -14.8%
Quality
8.9%·
ROCE (5y median)
ROE 6.9% (5y median) · margin 8.6%
Leverage
0.57·
Debt / Equity · moderate
Net debt ₹672 Cr
Revenue FY21→FY26
1.0×▼
Margin −10.6 pts
₹1,720 Cr → ₹1,713 Cr
Cash conversion
3.93×▲
Operating cash ÷ profit · 5 yrs
₹1,378 Cr on ₹351 Cr
Moves on a normal day
1.46%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/B#56/163
ROCE#162/183
ROE#149/166
Debt / Equity#141/166
EBITDA margin#110/165
Revenue growth#109/161
Profit growth#51/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Over 5 years it reported ₹351 Cr of profit and ₹1,378 Cr of operating cash — 3.93×
Profit is converting into cash
Concerns
Revenue shrinking over 5 years (0% a year)
Erratic profits — up in only 2 of the last 5 years
Carries more debt than its peers — 0.57× equity
higher than 85% of its 166 Pharmaceuticals peers

Charts

How has the market priced it — with filings on the timeline?

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from HIKAL LIMITED's filed financials and exchange disclosures

What does HIKAL LIMITED do?

HIKAL LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol HIKAL.

Is HIKAL LIMITED profitable?

No. Over the trailing twelve months HIKAL LIMITED reported a net loss of ₹34 Cr on revenue of ₹1,735 Cr.

Does HIKAL LIMITED pay a dividend?

Yes. The dividend yield is 0.49% at the current price.

Is HIKAL LIMITED debt-free?

No. It reported borrowings of ₹681 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹672 Cr after cash. Debt stands at 0.57× equity. That is higher than 85% of its 166 Pharmaceuticals peers.

How much does the HIKAL LIMITED share price move in a day?

On a typical session HIKAL LIMITED moves 1.46% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

When are HIKAL LIMITED's next results?

Financial Results on Tue, 3 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track HIKAL LIMITED's announcements?

Every NSE and BSE filing by HIKAL LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.